Sanjaykumar Hapani, MD
Hematology & Oncology · Edmond, OKNPI 1952508533
Payments from drug & device makers
Across 814 payments — averaging $182.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$40K
- AstraZeneca$15K
- Sun Pharmaceutical Industries Inc.$15K
- E.r. Squibb & Sons, L.L.C.$13K
- Dova Pharmaceuticals$13K
- Pharmacosmos Therapeutics Inc.$11K
- plus $42K from 54 others
What the payments were for
- Consulting fees$39,17831%
- Speaking & faculty fees$61,85349%
- Travel & lodging$6,2825%
- Food & beverage$15,04512%
- Education$9891%
- Gifts$200%
- Other$1,5951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$148,926 in reported general payments places this provider in the 80th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 185 | $2,550,004 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 190 | $2,533,496 |
| ImbruvicaIbrutinib | 139 | $2,193,550 |
| ProcritEpoetin Alfa | 481 | $1,691,136 |
| CabometyxCabozantinib S-Malate | 38 | $933,358 |
| XgevaDenosumab | 246 | $768,222 |
| JakafiRuxolitinib Phosphate | 39 | $659,561 |
| IbrancePalbociclib | 38 | $609,643 |
| Abiraterone Acetate | 238 | $539,815 |
| NyvepriaPegfilgrastim-Apgf | 121 | $454,265 |
| Lupron DepotLeuprolide Acetate | 40 | $453,926 |
| DopteletAvatrombopag Maleate | 22 | $382,389 |
| VonjoPacritinib Citrate | 13 | $323,236 |
| AlunbrigBrigatinib | 14 | $266,752 |
| Lanreotide Acetate | 33 | $258,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Ibrance, Nyvepria, Eliquis, Nivestym | $5,901 | $3,688,412438 claims |
| Astellas Pharma US IncXtandi | $870 | $2,550,004185 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $232 | $2,193,550139 claims |
| Johnson & JohnsonProcrit, Xarelto | $241 | $1,709,476500 claims |
| AmgenXgeva, Prolia | $190 | $810,623271 claims |
| AbbVieLupron Depot, Venclexta | $644 | $669,94454 claims |
| Incyte CorporationJakafi | $5,535 | $659,56139 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig, Ninlaro | $1,187 | $449,30628 claims |
| Dova PharmaceuticalsDoptelet | $12,784 | $382,38922 claims |
| AstraZenecaCalquence, Lynparza | $14,906 | $358,50726 claims |
| Bristol Myers SquibbRevlimid | $1,476 | $256,91614 claims |
| NovartisKisqali | $9,526 | $199,71412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Edmond
- Gus GonzalezEdmond$7K
- Susanna UlahannanPonca City$8.3M
- Adam AschOklahoma City$2M
- Adanma Anji Ayanambakkam AttanathiOklahoma City$1.9M
- Kevin WeibelTulsa$1.7M
- Hassan HatoumOklahoma City$1.4M
- Abdul Rafeh NaqashOklahoma City$1.1M
- Sami IbrahimiOklahoma City$1M
- Scott ColeTulsa$644K
- Carrie YuenOklahoma City$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.